E Dreary Day

Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. Another 2 FDA officials resigned over the Biogen aducanumab Alzheimer's drug, bringing the total of those stepping down to 5. This affects one of our shares.

Business newspaper article

image source


*Our stock in this area is Eisai, the Japanese partner, which soared a week ago on the BIIB approval. ESALY managed a 1.3% rise today after opening up 1.04% as it is no one-trick pony but is still below $100, at $97.42, roughly in the middle of its 52-wk US$ range.

*Takeda (NYSE-TAK), another Japanese drug major, may gain or lose tomorrow when our FDA decides on the new drug application for TAK-721 to treat eosinophilic esophagitis. TAK also boosted its license deal with Codexis, a US enzyme engineering firm in synthetic biology for a gene therapy for lysosomal storage disorder, a rare genetic disease, and three others. It is also developing a vaccine against dengue which works best when the patient has a severe case leading to hospitalization. TAK fell today on heavy volume.

*Newbie Organon spun out by Merck gained 2.63% today. OGN.

*After last week's boost to pharma small caps, today most are down. The big exception is Compugen of Israel which was boosted 10.5% because another developer of PIRI anti-cancer treatment, US Iteos, won a deal from Glaxo for its product, for $625 mn up front and up to $1.4 bn in milestones. GSK rose 0.42%. CGEN now is up only 7.82%.

*Astra-Zeneca, also British, lost 0.5% today. AZN.

*Danish Novo-Nordisk fell 0.3% despite a report that the diabetes market will grow by $30 bn from now to 2025. It specializes in insulin and weight loss. NVO.

*Swiss Novartis gained 0.54%. NVS.

*Roche, RHHBY, fell 0.3% but is now up 0.4% after a JNJ drug in combo with its Venclexta beat its earlier combo of Gazyva and chemotherapy according to reports from the European Hematology gathering. The drugs treat leukemia and the new variant left zero bone marrow cancer at all, vs 17.1% for the control group.

1 2 3 4
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Vivian Lewis 1 month ago Author's comment

dear William K. thanks as we are about to restart our on-line subscription service you are a prime potential client because you post bravos so often.

William K. 1 month ago Member's comment

As always, broad coverage that seems to be detailed enough. Like a good news announcement, but not an announcement of only good news.

Vivian Lewis 1 month ago Author's comment

dear William K

we are about to re-start our website payments system. you may want to sign up